Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients

Affiliations

Editorial

P Ingiliz et al. Aliment Pharmacol Ther. 2018 Jun.

. 2018 Jun;47(11):1551-1552.

doi: 10.1111/apt.14649.

¹ Center for Infectiology, Berlin, Germany.
² Hepatology Department, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany.

No abstract available

Comment on

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group. Van Hees S, et al. Aliment Pharmacol Ther. 2018 Apr;47(8):1170-1180. doi: 10.1111/apt.14560. Epub 2018 Mar 2. Aliment Pharmacol Ther. 2018. PMID: 29498078 Free PMC article.